Results 121 to 130 of about 3,813 (172)

New Drugs: Sildenafil citrate

open access: yesAustralian Prescriber, 1998
openaire   +1 more source

Sildenafil citrate-Associated priapism

Urology, 2000
We report the first case of priapism associated with the use of sildenafil citrate. The patient was a 28-year-old man with mild erectile dysfunction after penile trauma who self-treated with a 100-mg dose of sildenafil citrate, resulting in low-flow priapism. After aspiration and intracorporal injection of alpha-agonists, the priapism resolved.
R L, Sur, C J, Kane
openaire   +2 more sources

Sildenafil citrate: A therapeutic update

Clinical Therapeutics, 2001
Since its approval by the US Food and Drug Administration in March 1998, sildenafil citrate has been used by millions of men for the treatment of erectile dysfunction. Recent studies and consensus reports have expanded our understanding of its efficacy, safety, contraindications, and drug interactions.This paper reviews recent studies of the efficacy ...
E G, Boyce, E M, Umland
openaire   +2 more sources

Physicochemical Properties of Sildenafil Citrate (Viagra) and Sildenafil Base

Journal of Pharmaceutical Sciences, 2003
Sildenafil citrate (Viagra) [I] and sildenafil base [II] are easily and unequivocally characterized by a set of physicochemical methods that include X-ray diffractometry, infrared spectroscopy, and thermal analysis. Monoclinic lattice constants: [I]: a = 26.98 A; b = 11.95 A; c = 16.68 A; beta = 106.97 degrees. [II]: a = 8.66 A; b = 34.27 A; c = 8.93 A;
Melnikov, P.   +4 more
openaire   +3 more sources

Viagra® (sildenafil citrate) and ophthalmology

Progress in Retinal and Eye Research, 2002
Viagra (sildenafil citrate) improves penile erections in men with erectile dysfunction (ED) by selectively inhibiting cGMP-specific phosphodiesterase type 5 (PDE5), which is present in all vascular tissue. It also exerts a minor inhibitory action against PDE6, which is present exclusively in rod and cone photoreceptors.
Alan, Laties, Eberhart, Zrenner
openaire   +2 more sources

Safety of sildenafil citrate

The Lancet, 1998
Sir—In your editorial on sildenafil citrate (Viagra), you state that “Public information to consumers and health professionals covers safety adequately, if not to the total satisfaction of consumer groups such as the US Public Citizen”. Although this editorial involved an internet search, we point out information that is not in the FDA-approved label ...
Sidney M Wolfe   +2 more
openaire   +1 more source

Sildenafil citrate (Viagra(R))

Drugs of Today, 2000
Sildenafil citrate, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type V (PDE V), initially designated as compound 92-480-10 by Pfizer, was studied in the late 1980s as an antianginal. An unexpected side effect of the early clinical investigations was improved erectile function among the men studied.
openaire   +2 more sources

Overall cardiovascular profile of sildenafil citrate

The American Journal of Cardiology, 1999
Sildenafil, a selective inhibitor of phosphodiesterase type 5 (PDE5), is the first in a new class of orally effective treatments for erectile dysfunction. During sexual stimulation, the cavernous nerves release nitric oxide (NO), which induces cyclic guanosine monophosphate (cGMP) formation and smooth muscle relaxation in the corpus cavernosum ...
R M, Zusman   +3 more
openaire   +2 more sources

Effects of Sildenafil Citrate on Defibrillation Efficacy

Journal of Cardiovascular Electrophysiology, 2006
Introduction: Although fatal arrhythmia and sudden death have been reported in patients taking sildenafil citrate, its effect on defibrillation efficacy has not been investigated. The aim of this study was to test the hypothesis that sildenafil citrate increases the shock strength required to successfully defibrillate during ventricular fibrillation ...
Krekwit, Shinlapawittayatorn   +3 more
openaire   +2 more sources

Sildenafil citrate for the treatment of pulmonary hypertension

Drugs of Today, 2006
Pulmonary arterial hypertension is a progressive disease that has a high rate of mortality. For these reasons, early treatment is essential. Treatment choices for pulmonary arterial hypertension are limited by drug tolerability, drug cost and inconvenience associated with administration techniques and dosing schedules.
Sandra L, Hrometz, Kelly M, Shields
openaire   +2 more sources

Home - About - Disclaimer - Privacy